Validity of conclusions on treatment efficacy: Difficulties in patient recruitment and a large number of drop-outs may lead to bias

Validity of conclusions on treatment efficacy: Difficulties in patient recruitment and a large... Hougaard etal. [1] in this issue of the Scandinavian Journal of Pain report on a randomised, double blind, placebo controlled cross-over study in the aura phase of migraine from which we can learn a great deal about trial design and generalisability of trial results.NXN-188 is an oral dual action nNOS-inhibitor and 5HT1B/1D receptor agonist. A total of 50 patients were randomised between two different sequences of NXN-188 and placebo. However, only 18 patients completed the trial and were available for the planned analysis. No statistically significant difference between NXN-188 and placebo was demonstrated. As stated by the authors, the low number of patients completing the study prevents a firm conclusion on lack of efficacy. Nevertheless, the results presented do not seem very promising.The authors have experienced large problems recruiting patients to the trial and have faced an unexpectedly high propor-tion of drop-outs before the second treatment period. Probably they would have been hesitant to initiate this trial had they known that the final statistical analysis would include only 18 completers. The figure illustrating patient disposition illustrates their challenge. Out of 615 patients contacted by telephone 563 did not meet entry criteria or did not wish to participate in the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Scandinavian Journal of Pain de Gruyter

Validity of conclusions on treatment efficacy: Difficulties in patient recruitment and a large number of drop-outs may lead to bias

Loading next page...
 
/lp/degruyter/validity-of-conclusions-on-treatment-efficacy-difficulties-in-patient-Z412jWIgP8
Publisher
De Gruyter
Copyright
© 2012 Scandinavian Association for the Study of Pain
ISSN
1877-8860
eISSN
1877-8879
D.O.I.
10.1016/j.sjpain.2012.09.006
Publisher site
See Article on Publisher Site

Abstract

Hougaard etal. [1] in this issue of the Scandinavian Journal of Pain report on a randomised, double blind, placebo controlled cross-over study in the aura phase of migraine from which we can learn a great deal about trial design and generalisability of trial results.NXN-188 is an oral dual action nNOS-inhibitor and 5HT1B/1D receptor agonist. A total of 50 patients were randomised between two different sequences of NXN-188 and placebo. However, only 18 patients completed the trial and were available for the planned analysis. No statistically significant difference between NXN-188 and placebo was demonstrated. As stated by the authors, the low number of patients completing the study prevents a firm conclusion on lack of efficacy. Nevertheless, the results presented do not seem very promising.The authors have experienced large problems recruiting patients to the trial and have faced an unexpectedly high propor-tion of drop-outs before the second treatment period. Probably they would have been hesitant to initiate this trial had they known that the final statistical analysis would include only 18 completers. The figure illustrating patient disposition illustrates their challenge. Out of 615 patients contacted by telephone 563 did not meet entry criteria or did not wish to participate in the

Journal

Scandinavian Journal of Painde Gruyter

Published: Dec 29, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial